Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC62615 structure
    GC62615AS-99
    CAS: 2323623-93-2

    AS-99 是一流的、有效的、选择性的 ASH1L 组蛋白甲基转移酶抑制剂(IC50=0.79μ;M,Kd=0.89μ;M),具有抗白血病活性。 AS-99 阻断细胞增殖,诱导细胞凋亡和分化,下调 MLL 融合靶基因,并减少体内白血病负担。

  • GC62620 structure
    GC62620NHWD-870
    CAS: 2115742-03-3
    纯度: >98.00%

    NHWD-870 inhibits CSF1 expression through suppressing BRD4 and its target HIF1α.

  • GC62621 structure
    GC62621Milademetan tosylate hydrate
    CAS: 2095625-97-9
    纯度: >98.00%

    Milademetan (DS-3032) tosylate hydrate 是特异性的、具有口服活性的 MDM2 抑制剂,用于急性髓系白血病和实体肿瘤的研究。Milademetan (DS-3032) tosylate hydrate 可诱导 G1 细胞周期阻滞、衰老和凋亡。

  • GC62626 structure
    GC62626ICCB-19 hydrochloride
    CAS: 1803605-68-6
    纯度: >99.00%

    ICCB-19 hydrochloride is an inhibitor of TNFRSF1A Associated Via Death Domain (TRADD) with IC50 of 1.12 μM and 2.01 μM for protecting Velcade-induced apoptosis in Jurkat cells and protecting RDA in MEFs, respectively. ICCB-19 indirectly inhibits Receptor-interacting serine/threonine-protein kinase 1 (RIPK1). ICCB-19 effectively induces autophagy.

  • GC62629 structure
    GC62629MB710
    CAS: 2230044-57-0

    MB710 是一种氨基苯并噻唑衍生物,是致癌 p53 突变体 Y220C 的稳定剂。MB710 与 Y220C 紧密结合并稳定 p53-Y220C,Kd 值为 4?μM。 MB710 在 p53-Y220C 细胞系中显示抗癌活性。

  • GC62630 structure
    GC62630TAS-117 hydrochloride
    纯度: >98.50%

    TAS-117 hydrochloride 是一种有效、选择性、具有口服活性的别构 Akt 抑制剂 (对 Akt1、2 和 3 的 IC50 分别为 4.8、1.6 和 44 nM)。TAS-117 hydrochloride 激发抗骨髓瘤活性并增强蛋白酶体抑制诱导的致命内质网应激。TAS-117 hydrochloride 诱导细胞凋亡 (apoptosis) 和自噬 (autophagy)。

  • GC62633 structure
    GC62633GGTI-2154
    CAS: 251577-10-3

    GGTI-2154 是一种有效和选择性的 geranylgeranyltransferase I (GGTase I) 抑制剂,IC50 值为 21 nM。GGTI-2154 对 GGTase I 的选择性是 FTase (IC50=5600 nM) 的 200 倍以上。GGTI-2154 可用于癌症的研究。

  • GC62639 structure
    GC62639rel-Zotatifin
    CAS: 2098191-54-7

    reli -Zotatifin是Zotatifin的外消旋异构体,作为eIF4A抑制剂,活性小于Zotatifin。Zotatifin (eFT226) 是一种有效,选择性和耐受性良好的 eIF4A 抑制剂。Zotatifin 可促进 eIF4A 与 5’-UTRs 中具有识别基序的特定 mRNA 序列结合 (IC50=2 nM),并干扰 eIF4F 起始复合物的组装。

  • GC62640 structure
    GC62640APG-1387
    CAS: 1570231-89-8
    纯度: >99.00%

    APG-1387 是一种二价 SMAC 模拟物,是 IAP 拮抗剂,可阻断 IAP 家族蛋白 (XIAP,cIAP-1,cIAP-2 和 ML-IAP) 的活性。APG-1387 诱导 cIAP-1 和 XIAP 蛋白降解以及 caspase-3 激活和 PARP 裂解,从而导致细胞凋亡。APG-1387 可用于肝细胞癌,卵巢癌和鼻咽癌的研究。

  • GC62641 structure
    GC62641WEHI-9625
    CAS: 2595314-46-6
    纯度: >99.00%

    WEHI-9625 是一种首创的,三环砜小分子凋亡抑制剂,EC50 值为 69 nM。WEHI-9625 与 VDAC2 结合可促进其抑制小鼠 BAK 诱导的细胞凋亡的能力,但对人 BAK 和与凋亡效应密切相关的 BAX 因子均完全无效。

  • GC62645 structure
    GC62645Fosifloxuridine nafalbenamide
    CAS: 1332837-31-6
    纯度: >98.00%

    Fosifloxuridine nafalbenamide (NUC-3373) 属于嘧啶核苷酸类似物,是一种胸腺嘧啶合酶 (Thymidylate synthase) 抑制剂。Fosifloxuridine nafalbenamide 具有抗癌活性。Fosifloxuridine nafalbenamide 具有诱发宿主免疫反应和增强免疫治疗的潜力。

  • GC62652 structure
    GC62652UZH1a
    纯度: >98.50%

    UZH1a 是一种有效和选择性的 METTL3 抑制剂,IC50 值为 280 nM。UZH1a 可用于细胞进程的转录组调控。UZH1a 具有抗肿瘤活性。UZH1a 也可用作研究 METTL3 的化学探针。

  • GC62654 structure
    GC62654GSK778
    CAS: 2451862-42-1
    纯度: >99.00%

    GSK778 (iBET-BD1) is a strong BD1 bromodomain inhibitor of the BET proteins, with IC50 value of 75 nM for BRD2 BD1, 41 nM for BRD3 BD1, 41 nM for BRD4 BD1, and 143 nM for BRDT BD1.

  • GC62657 structure
    GC62657MRIA9
    CAS: 2750707-05-0
    纯度: >98.00%

    MRIA9 是 ATP 竞争性的、pan-SIK 和 PAK2/3 抑制剂,其对 SIK1、SIK2 和 SIK3 的 IC50 值分别为 516 nM, 180 nM 和 127 nM。

  • GC62658 structure
    GC62658PD-1/PD-L1-IN 7
    CAS: 2374856-75-2
    纯度: >98.00%

    PD-1/PD-L1-IN 7 (PD-1/PD-L1-IN 7) 是一种人 PD-1/PD-L1 蛋白/蛋白相互作用抑制剂,IC50 为 0.213 nM。

  • GC62665 structure
    GC62665JAK2/FLT3-IN-1 TFA
    纯度: >98.50%

    JAK2/FLT3-IN-1 (TFA) 是一种口服有效的双重 JAK2/FLT3 抑制剂,对 JAK2,FLT3,JAK1 和 JAK3 的 IC50 分别为 0.7 nM,4 nM,26 nM 和 39 nM。JAK2/FLT3-IN-1 (TFA) 具有抗癌活性。

  • GC62676 structure
    GC62676TJ191
    CAS: 1522415-97-9
    纯度: >99.50%

    TJ191 is a selective anti-cancer small molecule that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells.

  • GC62682 structure
    GC62682BMSpep-57 hydrochloride
    纯度: >99.50%

    BMSpep-57 hydrochloride 是一种有效的大环肽类抑制剂,抑制 PD-1/PD-L1 相互作用,IC50 为 7.68 nM。BMSpep-57 hydrochloride 与 PD-L1 结合,MST 和 SPR 测定表明,Kd 分别为 19 nM 和 19.88 nM。BMSpep-57 hydrochloride 通过增加 PBMC 中 IL-2 的产生促进 T 细胞功能。

  • GC62688 structure
    GC62688INCB086550 (PD-1/PD-L1-IN-8)
    CAS: 2230911-59-6
    纯度: >98.00%

    INCB086550 (PD-1/PD-L1-IN-8)是一种强效的口服小分子PD-L1抑制剂,IC 50 值为3.1nM。

  • GC62693 structure
    GC62693SCR130
    CAS: 2377858-38-1
    纯度: >98.00%

    SCR130 is a novel DNA repair inhibitor with IC50s of 14 μM in Reh cells and 2 μM in Nalm6 cells. SCR130 specifically inhibits DNA Ligase IV‐mediated joining with minimal or no effect on Ligase III and Ligase I mediated joining.

  • GC62707 structure
    GC62707Murizatoclax
    CAS: 2245848-05-7

    Murizatoclax (AMG 397) 是一种有效,选择性和具有口服活性的髓样白血病 1 (MCL-1) 抑制剂,Ki 值为 15 pM。Murizatoclax 与促凋亡 BCL-2 家族成员竞争性结合 MCL1 的 BH3 结合沟。Murizatoclax 可用于癌症的研究。

  • GC62716 structure
    GC62716MD-222
    CAS: 2136246-72-3
    纯度: >99.00%

    MD-222 是一种首创的高效的基于 PROTAC 的 MDM2 降解剂。MD-222 诱导 MDM2 蛋白快速降解并激活细胞中的野生型 p53。MD-222 具有抗癌作用。

  • GC62777 structure
    GC627772-Methoxy-4-vinylphenol
    CAS: 7786-61-0
    纯度: >98.00%

    2-Methoxy-4-vinylphenol (2M4VP) 是天然的发芽抑制剂,具有抗炎活性。

  • GC62871 structure
    GC62871BM-1244
    CAS: 1619923-32-8
    纯度: >98.50%

    BM-1244 是一种有效的 Bcl-xL/Bcl-2 抑制剂,对 Bcl-xL 和 Bcl-2 的Ki 分别为 134 和 450 nM。BM-1244 抑制衰老成纤维细胞 (SnCs),EC50 为 5 nM。